1. What Is the Cardiac Resynchronisation Therapy (CRT) Device Market?
The Cardiac Resynchronisation Therapy (CRT) Device Market comprises implantable biventricular pacing systems designed to coordinate the mechanical contraction of the left and right ventricles in patients with cardiac dyssynchrony and heart failure. The market includes CRT pacemakers, CRT defibrillators, quadripolar left ventricular leads, coronary sinus lead systems, and associated device programming and remote monitoring platforms. These systems are implanted by electrophysiologists and cardiac surgeons in patients meeting guideline criteria for wide QRS morphology and impaired systolic function refractory to optimised medical therapy. Market scope covers device hardware, implant lead systems, and programming tools, and excludes standalone single-chamber or dual-chamber pacemakers without biventricular capability and standalone ICDs without resynchronisation function.
2. Cardiac Resynchronisation Therapy (CRT) Device Market Size & Forecast
3. Emerging Technologies
- Conduction system pacing technologies are emerging as a physiologically driven alternative to conventional biventricular stimulation in patients with suboptimal CRT response or unfavourable coronary sinus anatomy. Growing clinical interest in His-Purkinje.
- Quadripolar left ventricular lead technology is advancing multi-vector pacing capability, enabling selection among multiple stimulation configurations to avoid phrenic nerve capture while optimising resynchronisation benefit. Increasing adoption of quadripolar systems.
- Wireless left ventricular stimulation platforms are advancing the feasibility of biventricular pacing without a conventional coronary sinus lead through endovascular or pericardial acoustic transmission approaches Continued development. Growing industry adoption of this technology is motivating development.
- AI-assisted atrioventricular and interventricular delay optimisation algorithms are expanding automated device programming beyond manual echocardiographic guidance at implant centres. Growing integration of device-based haemodynamic sensors with machine learning optimisation tools is reducing time required.
Similar technologies are also transforming adjacent markets. Learn more in our Cardiac Monitor Market.
4. Key Market Opportunity
One of the key opportunities in the Cardiac Resynchronisation Therapy (CRT) Device Market is the expansion of CRT therapy to heart failure patients with mildly reduced ejection fraction who currently fall outside guideline-supported implantation criteria. A substantial proportion of patients with ejection fraction between 36% and 50% and wide QRS morphology do not receive CRT despite haemodynamic impairment and hospitalisation risk comparable to guideline-eligible recipients. Completion of prospective randomised trials in non-traditional indication groups and the resulting guideline revisions from major cardiology societies are expected to open new implantation volumes at heart failure programmes globally. Manufacturers that adapt device platforms for expanded indications and provide supporting clinical education and registry infrastructure are positioned to capture first-mover advantage in the newly eligible patient cohort.
5. Top Companies in the Cardiac Resynchronisation Therapy (CRT) Device Market
The following organisations hold leading positions in the Cardiac Resynchronisation Therapy (CRT) Device Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Medtronic
- Abbott
- Boston Scientific
- Biotronik
- MicroPort CRM
- EBR Systems
- Cairdac
- Stimios
- LivaNova
- Medico Electronica
6. Market Segmentation
The Cardiac Resynchronisation Therapy (CRT) Device Market is analysed across 6 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Device Type | CRT Pacemaker Standard CRT-P MRI-Conditional CRT-P CRT Defibrillator Standard CRT-D High-Voltage CRT-D Extravascular CRT Wireless Left Ventricular Stimulation CRT |
| By Lead Configuration | Biventricular with Coronary Sinus Lead Standard Bipolar Left Ventricular Lead Quadripolar Left Ventricular Lead Conduction System Pacing His-Bundle Pacing Lead Left Bundle Branch Area Pacing Lead Wireless Left Ventricular Acoustic Endovascular Stimulation |
| By Application | Ischaemic Cardiomyopathy LBBB Morphology Ischaemic Non-LBBB Ischaemic Cardiomyopathy Non-Ischaemic Cardiomyopathy LBBB Morphology Non-Ischaemic Mildly Reduced EF Non-Ischaemic Atrial Fibrillation with Heart Failure Persistent AF with Reduced EF |
| By Heart Failure Severity | NYHA Class II Mildly Symptomatic Ambulatory HF NYHA Class III Moderately Symptomatic HF NYHA Class IV Severely Symptomatic Advanced HF |
| By End User | Hospitals Academic Heart Failure and Electrophysiology Centres Community Hospital Cardiac Departments Heart Failure Specialty Programmes Dedicated CRT Implant Services Multidisciplinary Heart Failure Teams Cardiac Electrophysiology Centres University Electrophysiology Laboratories |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Cardiac Resynchronisation Therapy (CRT) Device Market trajectory over the forecast period:
Expanded CRT Indications in Mildly Reduced Ejection Fraction Are Widening the Eligible Patient Population.Published evidence supporting CRT efficacy in heart failure patients with ejection fraction between 36% and 50% is prompting cardiology societies to consider revising guideline thresholds beyond the traditional 35% criterion. Medtronic completed enrolment in its MAESTRO trial evaluating CRT pacemaker efficacy in non-left bundle branch block morphology patients in 2024, targeting a population historically excluded from resynchronisation therapy guidelines.
Conduction System Pacing Is Emerging as a Physiologically Superior Alternative to Biventricular Stimulation in Select Patients.His-Purkinje network pacing and left bundle branch area pacing produce more physiological ventricular activation patterns than biventricular epicardial stimulation, achieving narrower QRS durations and improved echocardiographic synchrony in conventional CRT non-responders. Abbott expanded its commercial training programme for left bundle branch area pacing implantation at European electrophysiology centres in 2024, supporting adoption of conduction system pacing outside dedicated academic programmes.
Quadripolar Left Ventricular Lead Systems Are Reducing Phrenic Nerve Stimulation and Programming Complexity in CRT.Multiple pacing vectors available through four-electrode left ventricular leads enable clinicians to configure stimulation pathways that avoid phrenic nerve capture while maintaining resynchronisation efficacy and patient comfort. Boston Scientific reported expanded adoption of its ACUITY X4 quadripolar lead system during 2024, citing reduced programming time and improved chronic pacing thresholds in published real-world clinical data.
For related market intelligence, see the Cardiac Rhythm Management Market.
8. Segmental Analysis
By device type, the CRT defibrillator segment dominated the Cardiac Resynchronisation Therapy (CRT) Device Market in 2025, driven by the high proportion of CRT-eligible patients also requiring sudden death prevention. Electrophysiologists implanting CRT-D at guideline-endorsed rates in patients meeting dual indications for resynchronisation and ICD therapy generate consistent device demand across major cardiac centres globally. The CRT pacemaker segment is the fastest-growing device type category, driven by expanding indications in heart failure patients with low sudden cardiac death risk and growing conduction system pacing adoption. Cardiologists are increasing CRT-P implantation rates as published evidence and updated guidelines expand resynchronisation therapy to patient populations previously excluded from biventricular pacing criteria.
By application, non-ischaemic cardiomyopathy dominated the Cardiac Resynchronisation Therapy (CRT) Device Market in 2025, driven by a higher proportion of non-ischaemic patients presenting with left bundle branch block morphology at heart failure referral. Heart failure cardiologists continue directing CRT referrals toward non-ischaemic patients with LBBB morphology, who demonstrate superior echocardiographic response and greater long-term haemodynamic benefit than non-LBBB counterparts. Ischaemic cardiomyopathy is the fastest-growing application, driven by improving long-term survival following coronary revascularisation that expands the pool of patients reaching stable heart failure requiring device therapy. Cardiac surgeons and interventional cardiologists are increasing post-revascularisation referrals to heart failure programmes where CRT eligibility is assessed in patients with persistent reduced ejection fraction after complete revascularisation.
9. Regional Analysis
Regional demand patterns across the Cardiac Resynchronisation Therapy (CRT) Device Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Cardiac Resynchronisation Therapy (CRT) Device Market in 2025, with a market share of 42.0%. The region's leadership reflects high heart failure prevalence among ageing populations, well-established guideline-driven implantation protocols at major cardiology centres, and the presence of leading CRT device manufacturers in the United States. Comprehensive private and federal reimbursement for CRT implants and generator replacements creates consistent procedural volume across academic and community heart failure programmes. Earlier regulatory approvals for advanced CRT configurations including quadripolar leads and wireless left ventricular stimulation in the United States position North America at the forefront of CRT technology adoption.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 8.70% during the forecast period. Growing diagnosis rates for heart failure with reduced ejection fraction in China, Japan, South Korea, and India are expanding the treatable patient population eligible for CRT implantation at major tertiary hospitals. National health insurance coverage expansion in several Asia Pacific economies is improving access to cardiac resynchronisation therapy for patients who previously lacked reimbursement for the procedure and device costs. Increasing electrophysiologist and cardiac surgeon training programmes in the region are reducing the skills gap that historically limited CRT implantation volumes at non-academic centres.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Cardiac Resynchronisation Therapy (CRT) Device Market was valued at USD 6.76 Bn in 2025 and is projected to reach USD 11.22 Bn by 2034, growing at a CAGR of 5.80% over the 2026–2034 forecast period.
The Cardiac Resynchronisation Therapy (CRT) Device Market is projected to grow at a CAGR of 5.80% from 2026 to 2034.
North America dominated the Cardiac Resynchronisation Therapy (CRT) Device Market in 2025, with a market share of 42.0%.
The leading companies in the Cardiac Resynchronisation Therapy (CRT) Device Market include Medtronic, Abbott, Boston Scientific, Biotronik, MicroPort CRM, EBR Systems, Cairdac, Stimios, LivaNova, Medico Electronica.
Expanded crt indications in mildly reduced ejection fraction are widening the eligible patient population.
By device type, the CRT defibrillator segment dominated the Cardiac Resynchronisation Therapy (CRT) Device Market in 2025, driven by the high proportion of CRT-eligible patients also requiring sudden death prevention.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.